Emricasan

Emricasan (IDN-6556, PF-03491390) is a potential drug invented in 1998 by Idun Pharmaceuticals.^[1][2] The drug was acquired by Pfizer in 2005^[3] and then sold to Conatus Pharmaceuticals in 2010.^[1] Conatus in turn licensed emricasan to Novartis in 2017 for exclusive development and commercialization.^[4]

Emricasan

Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name (3S)-3-{[(2S)-2-{[2-(2-tert-butylanilino)-2-oxoacetyl]amino}propanoyl]amino}-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
CAS Number	254750-02-2 Y
PubChem CID	12000240
ChemSpider	10172707
UNII	P0GMS9N47Q
KEGG	D10004
CompTox Dashboard (EPA)	DTXSID10180160
Chemical and physical data
Formula	C26H27F4N3O7
Molar mass	569.510 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(c(cc(c1F)F)F)F)NC(=O)C(=O)Nc2ccccc2C(C)(C)C
InChI InChI=1S/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1 Key:SCVHJVCATBPIHN-SJCJKPOMSA-N

The substance acts as a pan-caspase inhibitor and has antiapoptotic and antiinflammatory effects.^[4] It was developed for the treatment of liver disease^[5] and has been granted fast track designation by the FDA for the treatment of non-alcoholic steatohepatitis cirrhosis^[6][7][8] The substance is the first pan-caspase inhibitor to advance to broad clinical testing, and its novel mechanism of action has led to research using it for other potential applications.^[9][10]